Biomarkers

A dedicated 2-day hybrid meeting with a focus on paving the road to laboratory
digitalisation through automation, robotics and cutting-edge informatics tools & technologies. 3 interactive tracks aiding the acceleration of laboratory digitalisation within the pharmaceutical industry: from setting up the labs of the future through to the application of automation and robotics & the implementation of state of-the-art IT tools and technologies.

Immuno-Oncology (IO) 360° takes a strategic look at the business and scientific aspects of Immuno-Oncology.  With significant in-put from Lead Advisors Dr. Axel Hoos (former CEO of Scorpion Therapeutics) and Dr. James Gulley (NCI,) the conference examines the current landscape, and reports on the latest advancements in IO to improve and accelerate clinical trials. The audience is comprised of roughly 500 top executives at Pharma companies and Biotechs, as well as the financial community, consultants and leading research organizations in the field of Immuno-Oncology.  

The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on, but access to funding and large patient cohorts, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress. The 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need.

“The Macrophage-directed Therapies Summit is returning for the 4th year, back to Boston – and continues to be the leading industry-focused forum uniting this emerging community of over 100 leaders to review cutting-edge advances in the discovery, preclinical, translational, and clinical development of macrophage-directed therapies.Covering discovery to the clinic and a brand-new Biomarkers Bootcamp, the summit is returning with two tracks of content.Join the likes of Gilead Sciences, Pionyr Immunotherapeutics, KAHR Medical, Codiak BioSciences, Ichnos Sciences, and Enlivex Therapeutics Ltd, and receive the latest updates on clinical progress, novel approaches, and targets to broaden the spectrum of macrophage targeting. With continuing growth in the macrophage space, delve into:
CD47 targeting and other ‘don’t eat me’ signals
Safety concerns due to model translatability and dosing
Optimal combination or monotherapy discovery
Learn from our expert speaker faculty, who will be sharing more exclusive new or unpublished insights than ever before.”

In vivo gene engineering is fast becoming known as the future of cell and gene therapy with incredible amounts of investment seen in 2021, including the recent Moderna and Metagenomi collaboration alongside the partnership between Abintus Bio and MSKCC, and Tidal acquisition by Sanofi.